Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam

NCT05744128 is registered in ClinicalTrials.gov with ImaginAb, Inc. as lead sponsor.

NCT NCT05744128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05744128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Positron Emission Tomography Repeatability Evaluation of Tissue Zirconium 89Zr Crefmirlimab Berdoxam
Lead sponsor
ImaginAb, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
February 16, 2023
Completion date
May 31, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, renal cell carcinoma